2/6
09:25 am
erna
Ernexa Therapeutics Announces Pricing of $10.5 Million Public Offering
High
Report
Ernexa Therapeutics Announces Pricing of $10.5 Million Public Offering
2/3
08:45 am
erna
Ernexa Therapeutics Participates in Virtual Investor “What This Means” Segment Highlighting Recent Successful Pre-IND Meeting with U.S. FDA
High
Report
Ernexa Therapeutics Participates in Virtual Investor “What This Means” Segment Highlighting Recent Successful Pre-IND Meeting with U.S. FDA
1/27
08:45 am
erna
Ernexa Therapeutics Selected as One of Only Ten Global Companies for Prestigious JETRO Japan Entry Acceleration Program
Medium
Report
Ernexa Therapeutics Selected as One of Only Ten Global Companies for Prestigious JETRO Japan Entry Acceleration Program
1/6
08:15 am
erna
Ernexa Therapeutics Announces Successful Pre-IND FDA Meeting and Continues Progress Toward First-in-Human Trial in Ovarian Cancer
Low
Report
Ernexa Therapeutics Announces Successful Pre-IND FDA Meeting and Continues Progress Toward First-in-Human Trial in Ovarian Cancer
12/8
08:30 am
erna
Ernexa Therapeutics Presents New Preclinical Data at American Society of Hematology (ASH) Annual Meeting on Lead Cell Therapy Candidate for Treatment of Ovarian Cancer
Low
Report
Ernexa Therapeutics Presents New Preclinical Data at American Society of Hematology (ASH) Annual Meeting on Lead Cell Therapy Candidate for Treatment of Ovarian Cancer
12/3
08:30 am
erna
Ernexa Therapeutics Announces Oral Presentation at the 67th American Society of Hematology (ASH) Annual Meeting
Medium
Report
Ernexa Therapeutics Announces Oral Presentation at the 67th American Society of Hematology (ASH) Annual Meeting
12/2
08:50 am
erna
Ernexa Therapeutics Strengthens Scientific and Medical Advisory Board with Appointment of Leading Oncologist Dr. Ira S. Winer, M.D., Ph.D., FACOG
Medium
Report
Ernexa Therapeutics Strengthens Scientific and Medical Advisory Board with Appointment of Leading Oncologist Dr. Ira S. Winer, M.D., Ph.D., FACOG